Corrections:

David King^1,*, Xiao Dun Li^2,#,*, Gilberto S. Almeida^3,4, Colin Kwok², Polly Gravells¹, Daniel Harrison¹, Saoirse Burke¹, Albert Hallsworth², Yann Jamin^3,4, Sally George², Simon P. Robinson^3,4, Christopher J. Lord⁵, Evon Poon², Daniel Yeomanson⁶, Louis Chesler² and Helen E. Bryant¹

¹Academic Unit of Molecular Oncology, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
²Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
³Divisions of Radiotherapy & Imaging, The Institute of Cancer Research, Sutton, UK
⁴The Children and Young People’s Unit, The Royal Marsden NHS Trust, Sutton, UK
⁵CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
⁶Sheffield Children’s Hospital, Western Bank, Sheffield, UK
^#Present address: Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge, UK
^*These authors contributed equally to this work

Published: January 12, 2023

Copyright: © 2023 King et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Supplementary Figure 2, under the IMR-32 column, the 3rd row, first panel image is an accidental duplicate of the 2nd row, 3rd panel image. The 6th row, 2nd panel image is also an accidental duplicate of the 7th row, 2nd panel image. In Supplementary Figure 11A, the 1st row, 2nd panel image was accidentally lifted from a student report as an example of IMR32 cells treated with DMSO. The corrected figures, obtained using the original data, are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2020; 11:2141–2159. DOI: https://doi.org/10.18632/oncotarget.27329

Supplementary Figure 2: PARP inhibitors olaparib, veliparib and talazoparib inhibit PARP in NB cells. Detection of PAR by immunofluorescence in IMR-32 and Shep-1 NB cell lines. Cells were pre-treated for 16 hours at the concentrations of PARP inhibitors as indicated. Treating cells with 150 μM H₂O₂ resulted in much stronger PAR activity in vehicle-treated cells and allowed PARP inhibition to be more clearly demonstrated. PAR (green), DAPI (blue).